Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 54.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 264,869 shares of the company’s stock after selling 322,000 shares during the period. Aberdeen Group plc owned 0.44% of Structure Therapeutics worth $18,422,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in GPCR. E. Ohman J or Asset Management AB bought a new position in Structure Therapeutics during the fourth quarter valued at about $314,000. Gilbert & Cook Inc. acquired a new stake in shares of Structure Therapeutics during the 4th quarter worth approximately $395,000. JPMorgan Chase & Co. grew its holdings in shares of Structure Therapeutics by 37.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 58,148 shares of the company’s stock worth $1,628,000 after purchasing an additional 15,706 shares in the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $6,856,000. Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of Structure Therapeutics during the 3rd quarter worth approximately $10,440,000. 91.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on GPCR shares. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. William Blair reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Structure Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Trading Down 3.2%

GPCR stock opened at $51.77 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $3.67 billion, a P/E ratio of -65.53 and a beta of -1.17. The business’s 50 day moving average is $63.91 and its 200-day moving average is $53.03.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.